PET-CT After Cilta-Cel CAR-T: Can Scans Predict Myeloma Relapse? | IMS 2026

Sharing a Myeloma, MGUS or Smoldering Myeloma Diagnosis: HealthTree Survey | IMS 2026

Newly Diagnosed With Myeloma? Join a Diet Study From Home | IMS 2026

Circulating Tumor Cells in Myeloma: Can a Blood Test Predict High-Risk Disease? | IMS 2026

Doctor-Checked AI Improves Flow Cytometry Data Extraction in Myeloma | IMS 2026

Blood-Based MRD Testing Correlates With Bone Marrow Testing in Multiple Myeloma -EasyM | IMS 2026

Second Cancers After Myeloma Stem Cell Transplant: What Is the Long-Term Risk? | IMS 2026

Iberdomide + Daratumumab More Than Doubles MRD-Negative Rates in Myeloma -EXCALIBER | IMS 2026

Whole-Body MRI in Smoldering Myeloma: Can It Predict Progression Risk? | IMS 2026

Belantamab + VRd for Newly Diagnosed Myeloma: What DREAMM-9 Shows About Vision

Outpatient Bispecifics: Keeping Myeloma Patients Out of the Hospital | IMS 2026 #myeloma

BCMA CAR-T for CNS Myeloma: Is It Safe and Effective for Brain or Spinal Fluid Disease? | IMS 2026

Myeloma Super Responders: What HealthTree Registry Data Reveals | IMS 2026

Does High Blood Sugar Affect CAR-T Outcomes in Multiple Myeloma? | IMS 2026

PERSEUS 6-Year Results: D-VRd Improves Myeloma PFS & Supports Dual Maintenance | IMS 2026

Can Myeloma Be Cured Even After Relapse? | IMS 2026